Jane Street Group LLC lifted its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 103.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 462,004 shares of the biopharmaceutical company's stock after acquiring an additional 234,528 shares during the period. Jane Street Group LLC owned 0.76% of Sage Therapeutics worth $2,509,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. US Bancorp DE increased its position in Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after buying an additional 2,268 shares in the last quarter. Teacher Retirement System of Texas grew its stake in Sage Therapeutics by 21.6% during the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock valued at $75,000 after purchasing an additional 2,446 shares during the last quarter. Picton Mahoney Asset Management grew its stake in Sage Therapeutics by 126.0% during the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 3,581 shares during the last quarter. Invesco Ltd. grew its stake in Sage Therapeutics by 5.3% during the 4th quarter. Invesco Ltd. now owns 92,528 shares of the biopharmaceutical company's stock valued at $502,000 after purchasing an additional 4,629 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in Sage Therapeutics by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 33,051 shares of the biopharmaceutical company's stock valued at $179,000 after purchasing an additional 7,087 shares during the last quarter. 99.22% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several research firms have weighed in on SAGE. HC Wainwright reiterated a "neutral" rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Bank of America began coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They set an "underperform" rating and a $5.00 price target on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a research note on Friday, April 25th. Wedbush reiterated a "neutral" rating and set a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group dropped their price target on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research note on Wednesday, February 12th. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $8.81.
Check Out Our Latest Analysis on Sage Therapeutics
Sage Therapeutics Price Performance
NASDAQ SAGE traded down $0.09 during trading hours on Wednesday, reaching $7.04. The company's stock had a trading volume of 15,800 shares, compared to its average volume of 1,199,669. The firm has a market capitalization of $440.79 million, a price-to-earnings ratio of -1.06 and a beta of 0.20. Sage Therapeutics, Inc. has a 1-year low of $4.62 and a 1-year high of $13.47. The company's 50-day moving average is $7.39 and its two-hundred day moving average is $6.72.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The business had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. During the same period in the previous year, the company posted ($1.80) EPS. The business's revenue for the quarter was up 78.0% compared to the same quarter last year. Equities analysts forecast that Sage Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.
About Sage Therapeutics
(
Free Report)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
See Also
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
